AMCP Corporate Member Spotlight: Dermavant Sciences
AMCP News & Views recently caught up with Dermavant Sciences to learn about the company and gain insights on becoming an AMCP Corporate Member.
As you considered becoming a Corporate Member, what tipped the scales?
Dermavant Sciences is a biopharmaceutical company committed to fostering unprecedented change and unparalleled impact in immuno-dermatology. We focus on developing therapies that have the potential to address high unmet medical needs while driving greater efficiency in research and clinical development. Our decision to become a Corporate Member of AMCP was driven entirely by our mutual goal to improve patient health, which is particularly important in dermatology where there is an enormous need to advance innovative solutions for people who have historically endured a frustrating trial-and-error process managing conditions like psoriasis and atopic dermatitis. Our relationship with AMCP allows us to maintain strong relationships with pharmacists, health care providers and other stakeholders that ultimately result in continued collaboration and clinical insights that help us advance meaningful change for patients.
What is your strategy and anticipated innovations for 2022?
We are proud to share that in May, the FDA approved our lead product candidate VTAMA® (tapinarof) cream, 1% for the treatment of plaque psoriasis in adults. Currently, the most prescribed topicals for psoriasis are steroids.i VTAMA cream is not a steroid; it is the first and only steroid-free topical medication in its class in the U.S. to treat adults with plaque psoriasis.ii Following more than 25 years of minimal innovation in the topical psoriasis treatment space, this approval results in a new, novel treatment for adults living with mild, moderate and severe plaque psoriasisiii¯ivvvi that can be used long-term — as demonstrated in clinical trials over 52 weeks — and on sensitive and difficult-to-treat skin areas, such as the face, groin, and underarms.vii¯viiiix
Looking ahead, we continue to leverage VTAMA cream’s active ingredient, tapinarof, to understand how it might be applied to other conditions to help as many patients with dermatological issues as possible. A separate phase 3 trial is evaluating VTAMA cream in children, and in September 2021, we dosed our first patient in our pivotal Phase 3 clinical trial program (ADORING 1 and ADORING 2) for VTAMA cream to treat patients aged 2 years and older with atopic dermatitis. We expect to receive topline Phase 3 results in atopic dermatitis in the first half of 2023.
IMPORTANT SAFETY INFORMATION
Indication: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in subjects treated with VTAMA® (tapinarof) cream, 1% were folliculitis (red raised bumps around the hair pores), nasopharyngitis (pain or swelling in the nose and throat), contact dermatitis (skin rash or irritation, including itching and redness, peeling, burning, or stinging), headache, pruritus (itching), and influenza (flu).
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088 or report side effects to Dermavant Sciences at 1-8 DERMAVANT (1-833-762-8268)
Please see full prescribing information here.
What’s your one-minute elevator speech about your company?
At Dermavant Sciences, our mission is to make healthier skin a reality for the millions of people around the world living with chronic skin conditions like psoriasis and atopic dermatitis, and we take this mission very seriously. Our perspective is that skin is more than superficial — it’s where we live every moment of every day, which is why we’re 100% dedicated to skin and helping those who struggle get the results they deserve. Our robust medical dermatology pipeline includes approved, late-stage and early development product candidates that target specific unmet needs in two of the largest growing immune-dermatology markets: plaque psoriasis and atopic dermatitis. Our practical, people-focused approach enables us to advance medicines that can improve health outcomes and make a meaningful difference in the lives of patients.
Learn more about becoming an AMCP Corporate Member.
